Maxim analyst Jason Kolbert reiterated a Buy rating on Biolinerx (NASDAQ:BLRX) with a price target of $7.00, as the company has completed its BL-7010 …
In a research report released yesterday, Roth Capital analyst Joseph Pantginis reaffirmed a Buy rating on Biolinerx (NASDAQ:BLRX) with an $8 price target, …
In a research report released Monday, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Biolinerx (NASDAQ:BLRX) with an $8 price target. The …
In a research report issued yesterday, Roth Capital analyst Joseph Pantginis maintained a Buy rating on Biolinerx (NASDAQ:BLRX) with an $8 price target, …
In a research report issued today, Maxim Group analyst Jason Kolbert maintained a Buy rating on Biolinerx (NASDAQ:BLRX) with a $7.00 price target, following the …
In a research report issued yesterday, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Biolinerx (NASDAQ:BLRX) with a price target of …
BioLineRx Ltd. (BLRX) today announced it received a Notice of Allowance of US patent for its Celiac disease candidate drug, BL-7010.
In a report released this morning, Roth Capital analyst Joseph Pantginis reinitiated coverage on BioLineRx Ltd. (BLRX) with a Buy rating and an $8.
